Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Bellicum Pharma Comm (NASDAQ: BLCM)

$12.04 USD -$0.86 (-6.67%)
Last Price $12.04
Net Change $-0.86 (-6.67%)
Bid $0
Ask Price $0
Open Price $12.9
Previous Close Price $12.9
High Price $13
Low Price $12
Number of Trades 20,574
Volume 4,748,300
Fifty Two Week High $23.11 (2016-11-14)
Fifty Two Week Low $7.57 (2016-03-29)
Average Daily Volume 500,842
Share Outstanding 27,160 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.74 (2017-03-13)
2nd Quarter Earnings $-0.66 (2016-11-09)
3nd Quarter Earnings $-0.61 (2016-08-08)
4th Quarter Earnings $-0.56 (2016-05-09)
PE Ratio $0
EPS Growth $-3.76
Recent Earnings $-0.74
Annual EPS $-2.57
Last Quarter EPS $
Market Capitalization $0.33B
Insider Shareholders % 0.233%
Annual Revenue $0B
No. Shares Outstanding 27,160
Inst. Shareholder % 71.99%
Annual Net Income $-0.07B
TTM Net Profit Margin $-18223.68
1-Year Return 52.21%
3-Year Return -49.58%
5-Year Return -49.58%
5-Year Revenue Growth 0%
5-Year Earnings Growth 0%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD -3.76%
Dividends per Share $
Stock Split Ratio
Beta 1.33
Bellicum Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer including both hematological and solid tumors as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501 an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201 a dendritic cell cancer vaccine which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals Inc. is based in Houston Texas.